Advaxis Invites Shareholders to the 2010 Advaxis Annual General Meeting

Place: NASDAQ MarketSite

4 Times Square, NYC

(43rd and Broadway)

Time: 10:00 a.m. EDT | Date: June 1, 2010

Meeting RSVP: [email protected] or the Advaxis facebook portal

_________________________________________________

*** SHAREHOLDER PROXY VOTES DUE MAY 27, 2010 ***

Proxy RSVP: www.SHAREHOLDERMATERIAL.com/ADXS

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, invites common stock shareholders and other interested parties to the 2010 Advaxis Annual General Meeting of shareholders (AGM).

Following the formal portion of the AGM, Advaxis Chairman/CEO Thomas A. Moore will provide an update on Company initiatives including the status of the Advaxis clinical trial program that include three (3) Phase II and one (1) Phase I in cervical cancer (2), cervical dysplasia (1) and head and neck cancer (1), respectively.

All shareholders not attending the AGM are encouraged to mail in their proxy votes as soon as possible as votes must be received no later than May 27, 2010. As an added convenience, investors can cast their vote on-line at:

www.SHAREHOLDERMATERIAL.com/ADXS.

For security purposes at the Nasdaq MarketSite, all investors attending the AGM are required to RSVP no later than May 27, 2010 at: [email protected] or find us on facebook and accept meeting invite.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590 (Office)
Executive Director
732-545-1084 (FAX)
[email protected]
or
Advaxis, Incorporated
Diana Moore, 732-545-1590 (Office)
Analyst
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.